Undisclosed KAT6 inhibitor / Hangzhou Innogate Pharma - LARVOL DELTA

Discovery of a highly potent KAT6 Inhibitor for potential treatment of advanced, metastatic and refractory ER+Her2- breast cancers (AACR 2025) - "Frequent genomic alteration of KAT6A and KAT6B have been found in a variety of cancer types. The molecule also exhibited good in vitro safety profile in hERG and well tolerated in rodent study. Collectively, these results provide preclinical evidence that our PCC molecule could be a superior KAT6A/6B inhibitor to treat patients with advanced, metastatic, refractory, fulvestrant-sensitive or-resistant, ER+Her2- breast cancers."

Metastases • Breast Cancer • Estrogen Receptor Positive Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • CCND1 • ER • HER-2 • KAT6A • KAT6B • KAT8